Medtronic Receives the US FDA's Approval for DiamondTemp Ablation System to Treat Atrial Fibrillation
Shots:
- The approval is based on DIAMOND-AF trial assessing the safety and efficacy of the DTA system vs contact force-sensing ablation system in 482 patients with recurrent- symptomatic- PAF whose condition is unresponsive to drug therapy
- Results: patient complication rate (96.7% vs 93.4%); primary effectiveness (79.1% vs 75.7%); procedural efficiencies with shorter total RF times- individual RF ablation duration and reduction in volume of infused saline
- The DTA system is the 1st FDA-approved- temperature-controlled- irrigated RF ablation system with diamonds currently available to deliver ablations
Ref: PRNewswire | Image: Mission Statement Academy
Click here to read the full press release
Tags
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com